List view / Grid view
30 June 2016 | By Victoria White, Digital Content Producer
The partnership will allow Probiodrug to utilise Crossbeta’s proprietary technology in support of Probiodrug’s biomarker development activities...
19 October 2015 | By Victoria White
Pyroglutamate-3 Abeta (pGlu-3 Abeta), a post-translational modified Abeta, is a highly toxic Abeta variant which is abundant in brains of patients with Alzheimer’s disease...
13 July 2015 | By Victoria White
Probiodrug is to provide funding to further investigate the potential of pGlu-Abeta antibodies for passive vaccination against Alzheimer's disease...
20 March 2015 | By Victoria White
Probiodrug has announced that the company will present data on its specific pGlu-Abeta mouse antibody 17/1 at AD/PDTM 2015 in Nice, France...
9 March 2015 | By Probiodrug
First patient enrolled at leading Alzheimer Center in Amsterdam...
3 March 2015 | By Probiodrug
Strong correlation between QCs and AD pathology in human brain biopsies underlines QC-inhibition as therapeutic approach...
29 October 2014 | By Probiodrug AG
Probiodrug AG, a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, has announced it is the Silver sponsor of the 5th Biannual NUBIN Symposium on Biomarkers in Neurodegenerative Disease taking place on October 29th and 30th in Amsterdam.
